Table 2.
Baseline Characteristics of ACTT-2 Participants, by Quartile of ACTT Risk Profile*
| Characteristic | Least Risk (n = 271) | Lower Risk (n = 236) | Moderate Risk (n = 221) | High Risk (n = 271) | Overall (n = 999) |
|---|---|---|---|---|---|
|
| |||||
| Median age (IQR), y | 50 (42–63) | 56 (42–67) | 57 (45–67) | 59 (47–69) | 56 (43–66) |
| Male sex, n (%)† Race, n (%) |
143 (53) | 142 (60) | 154 (70) | 193 (71) | 632 (63) |
| American Indian or Alaska Native | 3 (1.1) | 2 (0.8) | 3 (1.4) | 1 (0.4) | 9 (0.9) |
| Asian | 34 (13) | 26 (11) | 13 (6) | 26 (10) | 99 (10) |
| Black or African American | 56 (21) | 35 (15) | 30 (14) | 32 (12) | 153 (15) |
| White | 119 (44) | 114 (48) | 111 (50) | 132 (49) | 476 (48) |
| Hispanic or Latino ethnicity, n (%) | 128 (47) | 114 (48) | 111 (50) | 156 (58) | 509 (51) |
| Median body mass index (IQR), kg/m2 | 31.8 (27.5–38.2) | 30.8 (26.9–36.9) | 31.1 (26.7–35.7) | 29.4 (25.6–33.8) | 30.7 (26.6–36.0) |
| Median baseline CRP level (IQR), mg/L | 67.0 (34.1–113.2) | 108.0 (64.5–174.7) | 147.3 (93.9–204.6) | 174.2 (108.4–245.3) | 124.0 (64.4–190.0) |
| Median baseline log10 VL (IQR)‡ | 4.0 (0.0–5.1) | 4.2 (0.3–5.2) | 4.2 (2.5–5.3) | 4.5 (2.9–5.8) | 4.2 (1.4–5.4) |
| VL data, n (%)§ | 168 (62) | 162 (69) | 157 (71) | 171 (63) | 658 (66) |
| Median days from symptom onset to enrollment (IQR) | 8.0 (5.0–11.0) | 8.0 (6.0–11.0) | 8.0 (5.0–10.0) | 8.0 (5.0–10.0) | 8.0 (5.0–10.0) |
| Immunodeficiency, n (%) | 8 (3.0) | 8 (3.4) | 8 (3.6) | 6 (2.2) | 30 (3.0) |
ACTT = Adaptive COVID-19 Treatment Trial; CRP = C-reactive protein; VL = viral load.
*
Risk quartiles were derived from ACTT-1 and ACTT-2 participants combined.
†
Percentages are among participants in the specified risk quartile.
‡
Collected via oropharyngeal or nasopharyngeal swab.
§
Collection was planned only for a subset of participants.